Sight Sciences, Inc. SGHT
- Market cap
- $478.2M
- P/E
- 0.0×
Follow SGHT
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 17.00 | 5.35 | 1.04 | 3.30 | 2.03 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 42.57 | 18.40 | 15.30 | 8.45 | 9.24 |
High Price
|
|||
| — | — | — | — | 184 | 212 | 250 | 214 | 216 | 186 |
Employees
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | 8 | 23 | 28 | 49 | 71 | 81 | 80 | 77 |
Revenue
|
|||
| — | — | 68.95% | 71.97% | 66.68% | 82.41% | 82.67% | 85.34% | 85.50% | 86.17% |
Gross Margin
|
|||
| — | — | (14) | (26) | (35) | (63) | (86) | (55) | (51) | (38) |
EBT
|
|||
| — | — | (189.85%) | (110.76%) | (125.30%) | (128.22%) | (120.84%) | (68.39%) | (64.20%) | (49.66%) |
EBT Margin
|
|||
| — | 0 | (14) | (26) | (35) | (63) | (86) | (56) | (52) | (38) |
Net Income
|
|||
| — | — | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Depreciation
|
|||
| — | — | 0.16 | 0.50 | 2.95 | 1.83 | 1.49 | 1.67 | 1.59 | 1.48 |
Revenue/Sh
|
|||
| — | — | (0.31) | (0.55) | (3.71) | (2.36) | (1.80) | (1.14) | (1.03) | (0.74) |
Earnings/Sh
|
|||
| — | — | (0.31) | (0.53) | (3.44) | (1.97) | (1.59) | (0.97) | (0.45) | (0.57) |
Cash Flow/Sh
|
|||
| — | — | 0.00 | 0.00 | (0.10) | (0.03) | (0.02) | (0.02) | (0.01) | 0.00 |
Capex/Sh
|
|||
| — | — | (0.31) | (0.53) | (3.54) | (2.00) | (1.61) | (0.99) | (0.45) | (0.57) |
Free CF/Sh
|
|||
| — | — | (0.62) | (1.17) | (9.50) | 8.68 | 3.35 | 2.47 | 1.75 | 1.23 |
Book Value/Sh
|
|||
| — | — | 47 | 47 | 9 | 27 | 48 | 49 | 50 | 52 |
Shares
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | 8.29 | 8.29 | 8.29 | 9.59 | 8.26 | 3.06 | 2.28 | 5.35 |
PS Ratio
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 2.02 | 3.68 | 2.06 | 2.09 | 6.47 |
PB Ratio
|
|||
| — | — | 8.21 | 8.21 | 8.21 | 4.95 | 6.15 | 1.77 | 1.30 | 4.71 |
EV/Sales
|
|||
| — | — | (7.37) | (7.37) | (7.37) | (4.54) | (5.70) | (3.00) | (4.56) | (12.11) |
EV/FCF
|
|||
| — | — | (14) | (25) | (32) | (53) | (76) | (47) | (22) | (30) |
Op' Cash Flow
|
|||
| — | — | (1) | (1) | (1) | (1) | (1) | (1) | 0 | 0 |
Capex
|
|||
| — | — | (14) | (25) | (33) | (53) | (77) | (48) | (23) | (30) |
FCF
|
|||
| — | — | 4 | 21 | 61 | 264 | 192 | 151 | 124 | 102 |
Working Cap'
|
|||
| — | — | 34 | 78 | 32 | 33 | 34 | 34 | 39 | 40 |
Total Debt
|
|||
| — | — | 30 | 57 | (29) | (228) | (151) | (104) | (81) | (52) |
Net Debt
|
|||
| — | — | (29) | (55) | (89) | 232 | 160 | 120 | 88 | 64 |
Sh' Equity
|
|||
| — | — | (353.10%) | (133.23%) | (67.01%) | (35.67%) | (34.97%) | (29.26%) | (33.29%) | (29.77%) |
ROA
|
|||
| — | — | 0.00% | 0.00% | 0.00% | (701.56%) | (556.90%) | (223.54%) | (484.25%) | (188.86%) |
ROIC
|
|||
| — | — | 34.17% | 61.85% | 48.34% | (87.90%) | (43.98%) | (39.64%) | (49.59%) | (50.74%) |
ROE
|
|||
Sight Sciences, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NPCE NeuroPace, Inc. | $479.5M | 0.0× | Compare |
| PACB Pacific Biosciences of California, Inc. | $484.9M | 0.0× | Compare |
| MASS 908 Devices Inc. | $492.7M | 0.0× | Compare |
| CLPT ClearPoint Neuro, Inc. | $445.7M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TCMD Tactile Systems Technology, Inc. | $518.5M | 20.7× | Compare |
| CERS Cerus Corporation | $524.0M | 0.0× | Compare |
| BWAY Brainsway Ltd. Sponsored ADR | $531.6M | 28.9× | Compare |
| SENS Senseonics Holdings, Inc. | $546.7M | 0.0× | Compare |
Sight Sciences, Inc. (SGHT) key facts
- Sight Sciences, Inc. (SGHT) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Sight Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $77.4 million, down 3.13% from fiscal 2024.
- Sight Sciences, Inc. reported a net loss of $38.4 million, or a loss of $0.74 per share, for fiscal 2025.
- As of September 25, 2026, SGHT traded at $8.93, a market capitalization of $478.2 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 5.8× sales.
- Return on equity was −50.7% and debt-to-equity 0.77.
Sight Sciences, Inc. (SGHT) Latest News
19 Aug
Sight Sciences' TearCare becomes the first and only MGD treatment indicated to improve meibomian gland function in evaporative dry eye disease patients. New exclusive indication for core TearCare product drives major commercial and competitive gains for SGHT.
12 Aug
Sight Sciences (SGHT) released its Q2 2026 earnings call transcript covering financial results, operations, and outlook. Q2 2026 earnings details and forward guidance directly affect SGHT stock valuation and investor sentiment.
6 Aug
Sight Sciences reported record revenue growth in its Q2 2026 earnings call and raised guidance. Record revenue growth and raised guidance signal strong financial momentum that can materially lift stock valuation and future outlook.
Sight Sciences Q2 earnings call highlighted revenue figures, product performance for OMNI and TearCare systems, clinical updates, and forward guidance on growth and market expansion. Q2 earnings call delivered standard financial results and guidance that may influence near-term sentiment without major strategic shifts.
5 Aug
Sight Sciences secures Aetna coverage for OMNI and SION Surgical Systems. Aetna coverage expands reimbursement access for core products and supports revenue growth.
Sight Sciences, Inc. reported a Q2 net loss while exceeding revenue estimates. Q2 loss offset by revenue beat creates moderate short-term effects on financial perception and stock movement.
Sight Sciences reported second quarter 2026 financial results. Quarterly earnings releases can moderately shift near-term investor views on performance.
4 Aug
Sight Sciences receives FDA 510(k) clearance for the OMNI Ultra Surgical System. FDA clearance of OMNI Ultra Surgical System enables commercial launch and market expansion for Sight Sciences.
7 May
Sight Sciences, Inc. (SGHT) released Q1 earnings call highlights detailing financial results, revenue growth, operational updates, and future outlook. Q1 earnings highlights impact financial performance and investor sentiment moderately.
6 May
Sight Sciences, Inc. (SGHT) released Q1 2026 earnings call summary, highlighting quarterly financial results, revenue performance, operational updates, and forward guidance. Q1 earnings call summary provides critical financial metrics and outlook that significantly influence stock performance and investor expectations.
Sight Sciences (SGHT) Q1 earnings key metrics compared to Wall Street estimates. Q1 earnings comparisons to analyst estimates often trigger major stock price movements and shifts in investor expectations for future performance.
Sight Sciences (SGHT) Q1 2026 earnings call transcript details financial results, operational updates, and management's outlook for the quarter. Q1 2026 earnings transcript discloses key financial metrics, revenue growth, and strategic guidance directly impacting SGHT's valuation and market trajectory.
Sight Sciences, Inc. (SGHT) reported first-quarter 2026 financial results and raised full-year 2026 revenue guidance. Raising full-year revenue guidance after Q1 results signals strong growth momentum, likely driving significant positive shifts in investor sentiment and stock performance.
Sight Sciences, Inc. (SGHT) reported a Q1 net loss but beat revenue estimates. Q1 revenue beat despite loss moderately influences financial performance and investor sentiment.
1 Apr
Sight Sciences’ interventional technologies for glaucoma and dry eye disease will be featured in multiple clinical presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. Multiple clinical presentations at the prominent ASCRS meeting enhance visibility and credibility for Sight Sciences' core glaucoma and dry eye technologies.
30 Mar
Sight Sciences secures court order denying Alcon's post-trial motions, preserving the jury's verdict in Sight Sciences' favor and awarding monetary damages against Alcon and its Hydrus Microstent. Legal win upholds jury verdict and awards damages against competitor Alcon's product, bolstering SGHT's IP position and financial outlook.
5 Mar
Sight Sciences, Inc. (SGHT) Q4 2025 earnings call highlighted financial results, operational updates, and forward guidance. Q4 earnings summaries reveal revenue, profitability, and strategic outlook that significantly shape investor sentiment and stock trajectory.
Sight Sciences Inc (SGHT) Q4 2025 earnings call highlights revenue growth and strategic initiatives. Revenue growth and strategic initiatives in Q4 2025 earnings call represent major positive shifts for SGHT's financial trajectory and investor sentiment.
4 Mar
Sight Sciences reported Q4 earnings call highlights, covering financial results, revenue growth in OMNI and TearCare products, profitability progress, 2024 guidance, and strategic updates for the ophthalmic surgical device company. Q4 earnings highlights detail revenue beats, margin improvements, and raised guidance signaling significant positive trajectory shifts.
Sight Sciences (SGHT) released Q4 2025 earnings call transcript detailing financial results, revenue growth, profitability progress, and 2026 guidance. Q4 earnings transcript provides detailed financial outcomes, operational updates, and forward guidance that significantly influence investor sentiment and stock trajectory.
Sight Sciences (SGHT) reported Q4 earnings, emphasizing key metrics that reveal financial health and operational performance. Q4 earnings reports with key metrics significantly affect financial performance, investor sentiment, and stock trajectory.
Sight Sciences, Inc. (SGHT) reported fourth quarter and full-year 2025 financial results and initiated full-year 2026 financial guidance. Releasing quarterly/annual financial results and initiating new-year guidance significantly affects investor sentiment, stock price, and market performance.
Sight Sciences, Inc. (SGHT) reported a Q4 net loss but beat revenue estimates. Beating revenue estimates despite Q4 loss moderately boosts short-term market sentiment and highlights financial resilience.
25 Feb
Analysts expect Sight Sciences, Inc. (SGHT) to beat earnings estimates, raising potential for stock price gains. Expected earnings beat targets key financial performance and investor sentiment with moderate influence on stock trajectory.
13 Jan
Sight Sciences, Inc. (SGHT) has announced its preliminary, unaudited financial highlights for the fourth quarter and full year of 2025, indicating significant growth in revenue and product adoption. The company reported a notable increase in year-over-year revenue, driven by strong demand for its innovative ophthalmic products. Management expressed optimism about future performance and market expansion, highlighting strategic initiatives aimed at enhancing operational efficiency and customer engagement. The reported financial growth and strategic initiatives are likely to significantly impact the company's future performance and market positioning.
12 Jan
Sight Sciences, Inc. (SGHT) is navigating changes in Medicare coverage that could impact its market position and financial performance. The company is focusing on its innovative glaucoma treatment devices, which may benefit from increased reimbursement rates. Analysts are closely monitoring these developments as they could influence investor sentiment and the company's growth trajectory in the competitive ophthalmic market. Medicare coverage shifts are likely to significantly impact Sight Sciences' market dynamics and financial performance.
2 Jan
Sight Sciences, Inc. (SGHT) is highlighted for its potential growth and investment appeal due to recent advancements in its product offerings and market positioning. The company is focusing on innovative solutions in the ophthalmic space, which may enhance its competitive edge. Analysts suggest that the current market conditions and the company's strategic initiatives make it an attractive addition to investment portfolios. Significant product innovations and strategic positioning are likely to alter the company's trajectory and investor sentiment.
23 Dec
UBS has raised its price target for Sight Sciences, Inc. (SGHT) from $7 to $12, reflecting increased confidence in the company's growth potential and market performance. The price target increase indicates a moderately positive outlook on the company's financial performance and market sentiment.
18 Dec
Sight Sciences, Inc. (SGHT) is identified as a strong momentum stock due to its recent performance and growth potential in the ophthalmic market. The company has shown significant advancements in its product offerings, particularly in minimally invasive glaucoma surgery. Analysts highlight its robust financial metrics and increasing market demand, suggesting that SGHT is well-positioned for future growth. Investors are encouraged to consider buying shares as the company continues to innovate and expand its market presence. Significant advancements in product offerings and strong financial metrics indicate a likely positive impact on future performance.
5 Dec
Sight Sciences, Inc. (SGHT) reported Q4 earnings and sales that exceeded estimates, indicating strong financial performance. The adoption of its MyDay product has also seen an increase, suggesting positive market reception and growth potential. These developments reflect the company's effective strategies and may enhance investor confidence. Strong earnings performance and rising product adoption are likely to significantly impact future growth and investor sentiment.